
Oussama Darwish
@darwish_uroonc
Associate Professor, University at Buffalo. Urologic Oncology & Robotic Surgery. Views expressed here are my own.
ID: 844544671254745088
22-03-2017 13:41:55
241 Tweet
347 Followers
445 Following

Response rates for Enfortumab vedotin + pembrolizumab = 65% (n=76) in cisplatin ineligible 1st line urothelial cancer. Gem/carbo usually has RR of 40-45% (KN361, Danube etc). Even gem/Cis struggles to get >50%. Very promising. Details on PFS & OS awaited. businesswire.com/news/home/2022…


As #ESMO22 is approaching, here are my list of Top 15 #GU Oncology presentations, just based on "Titles"... This list may ultimately change after abstracts release esmo.org/meetings/esmo-… ESMO - Eur. Oncology Kate Kronig Federica Frigerio


Our 30-month #KYN564 adjuvant RCC trial is published The Lancet Oncology —led by Tom Powles, presented #GU22 ASCO —Note HR 0.63 improved from 0.68, all subgroups HR<1, AND if we remove M1NED/N+/T4=> HR 0.68. Still significant/clinically relevant OncoAlert sciencedirect.com/science/articl…




Oncological and safety profiles in patients undergoing simultaneous TURB and TURP Ekaterina Laukhtina Jeremy Teoh and colleagues for the EAU Young Academics Urothelial Carcinoma Working Group bjui.pub/3E5CCM5


THIS will be the ICING ON THE CAKE CUAJournal Amer. Urol. Assn. Canadian Urological Association Dean Elterman Bilal Chughtai Ricardo R Gonzalez MD Chris Morash Tony Finelli Andrew Feifer MD MPH Dr. Steven Kaplan malek meskawi upcoming 10 years--massive influx of patients 65+ & reduced urology workforce jamanetwork.com/journals/jaman…

ProtecT 15-yr PROs published overnight in NEJM Evidence: 🚩No diff in HRQoL 🚩Urine leakage (1+PPD): 24% in RP, 11% AM, 8% XRT 🚩Sexual function similar: 13% RP, 17% AM, 15% XRT 🚩Bowel function: 12% XRT vs 6% in RP/AM UroToday.com #EAU22


#EAU23 Riccardo Campi - Refining the indication for adjuvant Pembro in ccRCC at high risk of recurrence using a risk-adapted approach UroToday.com ♦️ 82.4%: malignant tumors ♦️ 54.1%: ccRCC ♦️ 419 (28.4%): eligible for adjuvant Pembro (int-high risk: 83%; high risk: 17%) 🧵


EAU 23: Treatment sequencing frameworks for mCPRC patients by BRCAm/HRRm status, courtesy of Dr. Christopher Evans UC Davis Urology UroToday.com #EAU23


Amazing presentation by Arnaud Méjean, MD, PhD at #UroOnco23. Back to more room for #cytoreductive #nephrectomy also for selected #intermediate IMDC risk patients.



AmJSurgery Finally, here’s a 2021 systematic review and meta-analysis on the topic: onlinelibrary.wiley.com/doi/10.1111/ja… Take home points: - 7 RCTs - rate of surgical glove perforation in the double-gloving group was lower than that of single gloving - surgical glove perforation was lower in the



The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by Amanda Myers

